---
title: "PDS Biotech publishes shareholder letter on strategic refocus to PDS0301"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295537526.md"
description: "PDS Biotechnology issued a shareholder letter announcing a strategic refocus on PDS0301 for metastatic colorectal cancer. The company will halt internal spending on PDS0101, including the Phase 3 VERSATILE-003 trial, and seek partners for its development. This decision follows promising Phase 2 data for PDS0301, showing high response rates in specific patient groups. A randomized Phase 2b program is planned with FDA feedback, targeting milestones over the next 18-24 months."
datetime: "2026-08-11T12:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295537526.md)
  - [en](https://longbridge.com/en/news/295537526.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295537526.md)
generator: "portal-rs"
---

# PDS Biotech publishes shareholder letter on strategic refocus to PDS0301

-   PDS Biotechnology issued a shareholder letter outlining a strategic refocus to prioritize PDS0301 in metastatic colorectal cancer. \* Internal spending on PDS0101 will stop, including discontinuation of the Phase 3 VERSATILE-003 trial; partnering sought for further development. \* Letter cited Phase 2 mCRC data showing 71% objective response rate at 6 months, 80% 24-month survival in MSS/pMMR patients with liver metastases. \* Randomized Phase 2b program for PDS0301 planned, designed with FDA feedback; milestones targeted over the next 18-24 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-032142), on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PDSB.US](https://longbridge.com/en/quote/PDSB.US.md)

## Related News & Research

- [PDS Biotechnology Says Lars Boesgaard To Resign As CFO Effective September 12](https://longbridge.com/en/news/296400297.md)
- [PDS Biotech holds annual shareholder meeting, quorum reached](https://longbridge.com/en/news/295931440.md)
- [Ebara publishes Investor’s Guide 2026 factsheet](https://longbridge.com/en/news/296725222.md)
- [Springer Nature signs 3-year transformative open-access deal with Binghamton University](https://longbridge.com/en/news/296506593.md)
- [Asmodee names Carly McGinnis chief product officer, EVP publishing, replacing de Barros](https://longbridge.com/en/news/296810520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**